Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPM2A | O95278 | 1/20 | 0.55 |
| ▸ | PTPRC | P08575 | 1/20 | 0.55 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.55 |
| ▸ | CDC14A | Q9UNH5 | 1/20 | 0.55 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 5/20 | 0.39 |
| ▸ | WNT3A | P56704 | 5/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL827855 | 0.73 | EPM2A (0.62) | EPM2APTPRCPTPN6CDC14APTPN22 | |
| SCHEMBL2493584 | 0.73 | EPM2A (0.51) | EPM2APTPRCPTPN6CDC14APTPN22 | |
| SCHEMBL30730407 | 0.71 | KCNN4 (0.46) | — | |
| SCHEMBL15590664 | 0.71 | EPM2A (0.59) | EPM2APTPRCPTPN6CDC14APTPN22 | |
| SCHEMBL30730227 | 0.70 | GAA (0.44) | IDO1 | |
| SCHEMBL27329721 | 0.70 | GAA (0.44) | IDO1 | |
| SCHEMBL3492979 | 0.70 | CTNNB1 (0.56) | HTR1BCTNNB1WNT3AIDO1NAMPT | |
| SCHEMBL2496329 | 0.70 | HTR1B (0.47) | EPM2APTPRCPTPN6CDC14APTPN22 | |
| SCHEMBL21781098 | 0.70 | BACE1 (0.45) | PIM1PIM2PLAU | |
| SCHEMBL1163268 | 0.70 | NPC1 (0.49) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966214-B9 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| EP-1966214-B9 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| EP-1966214-B1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-02 | — | — | EP | disclosed |
| EP-1966214-B1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-02 | — | — | EP | disclosed |
| US-8173654-B2 | Triazolopyridazine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-08 | — | — | US | disclosed |
| US-8173654-B2 | Triazolopyridazine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-08 | — | — | US | disclosed |
| US-8030305-B2 | Triazolopyridazines as kinase modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-10-04 | — | — | US | disclosed |
| US-8030305-B2 | Triazolopyridazines as kinase modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-10-04 | — | — | US | disclosed |
| US-20090098181-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-16 | — | — | US | disclosed |
| US-20090098181-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-16 | — | — | US | disclosed |
| EP-1966214-A1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2008-09-10 | — | — | EP | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
| WO-2007075567-A1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075567-A1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | RET, MET, ABL1 | EPM2A 2812/4885PTPRC 130/4885PTPN6 205/4885 |
| US-20090098181-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | RET, MET, ABL1 | EPM2A 2812/4885PTPRC 130/4885PTPN6 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.